<DOC>
	<DOCNO>NCT00281294</DOCNO>
	<brief_summary>To evaluate efficacy fontolizumab subject active rheumatoid arthritis determine 50 % improvement American College Rheumatology criterion ( ACR50 ) response Week 14 ( Stage A study ) .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety , Tolerability , Activity Fontolizumab Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>To evaluate efficacy fontolizumab subject active rheumatoid arthritis determine 50 % improvement American College Rheumatology criterion ( ACR50 ) response Week 14 ( Stage A study ) . Stage B trial Double blind .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female , least 18 year age A diagnosis RA accord ACR criterion ( Appendix D , American College Rheumatology Clinical Classification Criteria Rheumatoid Arthritis ) RA functional class I , II , III ( Appendix E , ACR Revised Criteria Classification Functional Status Rheumatoid Arthritis ) least 6 month Active RA ≥ 6 tender joint ≥ 6 swollen joint within one week dose Day 0 , dose Serum CRP ≥ 1.0 mg/dL ( 10 mg/L ) ≥ 45 minute morning stiffness On stable dos least 30 day receive study drug least one , two , follow diseasemodifying antirheumatic drug ( DMARDs ) : hydroxychloroquine , leflunomide , methotrexate ( leflunomidemethotrexate combination unacceptable ) , sulfasalazine . If treat nonsteroidal antiinflammatory drug ( NSAIDs ) lowdose prednisone ( ≤ 10 mg/day ) , must stable regimen least 14 day receive study drug Women childbearing potential negative serum pregnancy test screen Subjects reproductive potential agree use doublebarrier method contraception study 3 month receive last dose study drug Must provide sign date informed consent authorization use protect health information , ability understand study requirement , comply study procedure , include require study visit Significant involvement secondary RA ( eg , Felty 's syndrome , pulmonary fibrosis , Sjogren 's syndrome , vasculitis ( keratoconjunctivitis sicca exclusionary ) Received live vaccine within 30 day receive fontolizumab Received investigational agent within 30 day five halflives agent , whichever longer , receive fontolizumab Received corticosteroid injection joint , treat &gt; 10 mg/day corticosteroid within 30 day receive fontolizumab Received etanercept anakinra within 30 day receive fontolizumab Received gold salt , infliximab , adalimumab within 60 day receive fontolizumab Received IV gammaglobulin Prosorba column therapy within 90 day receive fontolizumab Received rituximab cyclophosphamide within 6 month receive fontolizumab Failed B cell recovery exposure rituximab History hypersensitivity glycine , histidine , Polysorbate 80 Pregnant woman nurse mother Malignancy within 5 year ( exclude basal squamous cell carcinoma skin adequately treat cervical carcinoma situ ) Known chronic viral infection HIV , hepatitis B , hepatitis C Clinical , PPD , clear radiographic evidence prior TB Infection require hospitalization parenteral medication , antibiotic , antiviral , antifungal , antiparasitic agent , within 90 day receive fontolizumab History inflammatory joint disease ( eg , gout , Lyme disease , psoriatic arthritis , reactive arthritis , seronegative spondyloarthropathy ) chronic inflammatory disease ( eg , inflammatory bowel disease , inflammatory myopathy , multiple sclerosis , overlap syndrome , scleroderma , systemic lupus erythematosus ) RA Clinically significant unstable poorly control acute chronic disease , myocardial infarction within 6 month , unstable angina , poorly control diabetes hypertension ALT &gt; 1.5 × upper limit normal ; AST &gt; 1.5 × upper limit normal ; creatinine 1.5 × upper limit normal ; absolute neutrophil count ( ANC ) &lt; 1000/mm3 ; platelet count &lt; 50,000/mm3 History medical disease , laboratory abnormality , psychological condition would make subject ( base upon principal investigator 's judgment ) unsuitable study enrollment Current abuse alcohol drug ( base upon investigator 's assessment ) Major surgery within 3 month prior plan elective surgery within 3 month last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
</DOC>